Systematic review examines IL-5-targeted and multi-target therapies for eosinophil-associated diseases including asthma and COPD.
A Tricky Immune Messenger Behind Severe Asthma
This systematic review evaluated IL-5-targeted therapies, multi-target combination therapies, bispecific antibodies, and small-molecule inhi…
A protein called IL-5 fuels severe asthma, but new drugs targeting multiple immune pathways at once may finally help patients who haven't re…
Mepolizumab plus FESS improved lung function and symptoms versus mepolizumab alone in severe CRSwNP.
When Your Nose and Lungs Are Fighting the Same War
This single randomized controlled trial enrolled 58 patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP) with or without a…
A biologic drug improves both sinus and lung symptoms in people with severe nasal polyps, and adding surgery helps the nose more but doesn't…
Mepolizumab fails to improve refractory chronic cough in small eosinophilic airways disease trial
Mepolizumab reduced inflammation but did not improve cough in a small study.
A single-centre randomised controlled trial of 30 patients with refractory chronic cough and eosinophilic airways disease found subcutaneous…
Mepolizumab lowered inflammation markers in patients with chronic cough but failed to reduce their coughing or improve their quality of life…